#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Zasocitinib (TAK-279) for Patients with Active Psoriatic Arthritis with Previous Biologic Treatment

3 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called zasocitinib, also known by its code name TAK-279, in people with a condition called psoriatic arthritis. Psoriatic arthritis is a type of arthritis that affects some people who have psoriasis, a condition that features red patches of skin topped with silvery scales. The study aims to evaluate how effective and safe zasocitinib is for treating this condition. Participants in the study will receive either zasocitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

The study will be conducted over a period of time, during which participants will take the medication in the form of a film-coated tablet. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will also consider the participants’ previous use of biologic treatments, which are advanced medications used to treat psoriatic arthritis.

Throughout the study, participants will be monitored to assess the medication’s impact on their condition. This includes looking at improvements in joint tenderness and swelling, as well as skin symptoms associated with psoriasis. The study will also evaluate changes in participants’ overall health and quality of life. The goal is to determine if zasocitinib can provide significant relief from the symptoms of psoriatic arthritis compared to the placebo. The study is expected to continue until 2028, with recruitment starting in 2025.

1 joining the study

Upon joining the study, you will be asked to provide your informed consent. This means you agree to participate and understand the study procedures and requirements.

You will need to confirm that you meet the eligibility criteria, such as being 18 years or older and having active psoriatic arthritis for at least 3 months.

2 initial assessment

An initial assessment will be conducted to evaluate your condition. This includes checking for at least 3 tender and 3 swollen joints and any active skin lesions.

Your current medications will be reviewed to ensure they are stable and meet the study’s requirements.

3 medication administration

You will be randomly assigned to receive either zasocitinib or a placebo. Both are taken as oral film-coated tablets.

The dosage and frequency will be determined by the study protocol, and you will be informed of the schedule.

4 ongoing monitoring

Throughout the study, regular visits will be scheduled to monitor your health and the effects of the medication.

You will be assessed for improvements in your condition, such as achieving a 20% improvement in symptoms by week 16.

5 final assessment

At the end of the study period, a final assessment will be conducted to evaluate the overall effectiveness and safety of the treatment.

You will be asked to provide feedback on your experience and any changes in your condition.

Who Can Join the Study?

  • The person must be willing and able to understand and follow the study procedures and requirements.
  • The person must provide written consent to participate in the study.
  • The person must be at least 18 years old.
  • The person must have had signs and symptoms of Psoriatic Arthritis (PsA) for at least 3 months.
  • The person must meet the Classification Criteria for Psoriatic Arthritis (CASPAR criteria), which are specific guidelines used to diagnose PsA.
  • The person must have active arthritis, shown by at least 3 tender and 3 swollen joints at the screening and baseline visits.
  • The person must have at least one active plaque psoriasis (PsO) lesion that is 2 cm or larger, or any nail changes characteristic of PsO.
  • The person must have had an inadequate response to certain medications for PsA, such as nonsteroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), or biologic DMARDs. This means the medications did not work well enough or caused side effects.
  • If the person is taking csDMARDs, they must be on no more than 2 of these medications for at least 12 weeks, with stable doses for at least 4 weeks before the study starts. Specific dose limits apply to medications like methotrexate (MTX), sulfasalazine (SSZ), leflunomide (LEF), and hydroxychloroquine (HCQ). The combination of MTX and LEF is not allowed.
  • If the person is taking other treatments for PsA, such as oral corticosteroids, NSAIDs, or certain pain relievers, the doses must be stable for at least 1 week before the study starts.
  • The person must meet specific birth control requirements if they have the potential to become pregnant. This includes being surgically sterile, confirmed postmenopausal, or agreeing to use a highly effective method of contraception during the study and for 10 days after the last dose. If using oral hormonal contraception, a second method should be used as well.

Who Cannot Join the Study?

  • Having any other active autoimmune disease, which means a condition where the immune system attacks the body.
  • Having a history of severe allergic reactions to medications.
  • Currently having an infection that requires treatment with antibiotics, antivirals, or antifungals.
  • Having a history of cancer within the last 5 years, except for certain types of skin cancer.
  • Being pregnant or breastfeeding.
  • Having a history of drug or alcohol abuse within the past year.
  • Having received any live vaccines within 4 weeks before starting the study.
  • Having any significant medical condition that the study doctors believe would make it unsafe to participate.
  • Currently participating in another clinical trial or having participated in one within the last 30 days.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Rheumatologische Facharztpraxis Magdeburg Germany
CENTRUM MEDYCZNE REUMA PARK Warsaw Poland
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Reumed Sp. z o.o. Lublin Poland
Hospital Quironsalud Sagrado Corazon Sevilla Spain
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH Hamburg Germany
Clinical Research Center Sp. z o.o. Medic-R sp.k. Poznan Poland
Centrum Medyczne All-Med Badania Kliniczne Cracow Poland
Accellacare Espana S.L. Alcobendas Spain
ISA Interdisciplinary Study Association GmbH Berlin Germany
Clinique De L’infirmerie Protestante De Lyon Caluire Et Cuire France
Medyczne Centrum Hetmanska Poznan Poland
Hospital Universitario Araba Vitoria Spain
Pratia S.A. Skorzewo Poland
St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Herne Germany
Hospital Universitario De Canarias La Laguna Spain
Universitaetsklinikum Leipzig AöR Leipzig Germany
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p. Elblag Poland
Cgmzhn Hzcbfotmhpc Ubbqdamhgcrbk Rjbmn Reims France
Hepzwnsf Uczhnlemvumda Mdvioqj Dt Vqrginhfix Santander Spain
Mygipldyb Ikxrgooohv Cyjfsikl Scxqjckh Sci z oqot Warsaw Poland
Cxjkdt Hqyuvuyclcx Rvukdraf Utzyargdvemfs Dh Tpvmo Tours France
Dljvsueudi Svi z oryn Wroclaw Poland
Fcuxnkxmb Phnp Ll Iwmgktyexzyow Bbzxsdpgn Das Hkukscao Upnenwjvnpdqn Ls Ptb Madrid Spain
Rhgoueuzmte Stfu Bidukp Ksmkuodkogo Mcurr Zozpcyhk Wroclaw Poland
Isldlyzg ds Cjuylrcesldg Hwukaealwcx Udoakxgedohhe dq Sdnza Earvejc (arhwccp Saint Priest En Jarez France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
19.05.2025
Germany Germany
Recruiting
19.05.2025
Poland Poland
Recruiting
19.05.2025
Spain Spain
Recruiting
19.05.2025

Trial locations

Investigated drugs:

Zasocitinib is a medication being studied for its potential to help people with psoriatic arthritis, a condition that causes joint pain and swelling. This medication works by targeting specific pathways in the immune system that are involved in causing inflammation. By doing so, it aims to reduce the symptoms of psoriatic arthritis, such as pain and swelling, and improve the overall quality of life for those affected by this condition. The study is looking at how effective and safe this medication is for people who have not responded well to other treatments.

Investigated diseases:

Psoriatic Arthritis – Psoriatic arthritis is a chronic inflammatory condition that affects the joints and is associated with psoriasis, a skin disease. It typically causes joint pain, stiffness, and swelling, which can vary in severity. The disease often progresses with periods of flare-ups and remissions. Over time, it can lead to joint damage and reduced mobility if not managed properly. Psoriatic arthritis can also affect other parts of the body, including the skin, nails, and eyes. The progression of the disease can be influenced by various factors, including genetic predisposition and environmental triggers.

Trial ID:
2024-513112-99-00
Protocol code:
TAK-279-PsA-3002
NCT ID:
NCT06671496
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Tulisokibart for Psoriatic Arthritis in Adults

    Recruiting

    2 1
    Investigated drugs:
    Germany Poland Spain

  • A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

    Recruiting

    2 1
    Czechia Germany Hungary Poland Spain